# US 2002/0058667 A1 · Compounds specific to adenosine A1 receptors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058667 A1
- Document ID: US20020058667A1
- Status: Published application
- Kind: A1
- Application number: 09/728,316
- Filed: 2000-12-01
- Published: 2002-05-16
- Earliest claimed: 1999-12-02
- Assignees: OSI Pharmaceuticals, Inc.
- Inventors: Arlindo L. Castelhano; Bryan McKibben; David J. Witter
- Web page: https://patentgrep.com/patent/US20020058667A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/06: Antiarrhythmics
- A61P 9/12: Antihypertensives
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.

## Claims

### Claim 1

A compound having the structure:
281
wherein R2 is a 5-6 membered aromatic ring; wherein R3 and R4 are independently H, or alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure:
282

### Claim 3 (depends on 2)

The compound of claim 2, having the structure:
283

### Claim 4 (depends on 2)

The compound of claim 2, having the structure:
284

### Claim 5 (depends on 2)

The compound of claim 2, having the structure:
285

### Claim 6 (depends on 2)

The compound of claim 2, having the structure:
286

### Claim 7

A compound having the structure:
287
wherein R2 is a 5-6 membered aromatic ring; wherein R3 and R4 are independently H, or alkyl; with the proviso that R2 is not 4-pyridyl.

### Claim 8 (depends on 7)

The compound of claim 7, having the structure:
288

### Claim 9

A compound having the structure:
289
wherein R2 is a substituted 5-6 membered aromatic ring;
wherein R3 and R4 are independently H, or alkyl.

### Claim 10 (depends on 9)

The compound of claim 9, having the structure:
290

### Claim 11

A compound having the structure:
291
wherein R2 is a 5-6 membered aromatic ring; wherein X is oxygen, or sulfur.

### Claim 12 (depends on 11)

The compound of claim 11, having the structure:
292

### Claim 13

A compound having the structure:
293
wherein R2 is a 5-6 membered aromatic ring; wherein X is oxygen, or sulfur.

### Claim 14 (depends on 13)

The compound of claim 13, having the structure:
294

### Claim 15 (depends on 1, 7, 9, 11)

A method for treating a disease associated with A1 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claims 1, 7, 9, 11, or 13.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a mammal.

### Claim 17 (depends on 16)

The method of claim 16, wherein the mammal is a human.

### Claim 18 (depends on 15)

The method of claim 15, wherein said A1 adenosine receptor is associated with cognitive disease, renal failure, cardiac arrhythmias, respiratory epithelia, transmitter release, sedation, vasoconstriction, bradycardia, negative cardiac inotropy and dromotropy, branchoconstriction, neutropil chemotaxis, reflux condition, or ulcerative condition.

### Claim 19 (depends on 1, 7, 9, 11)

A water-soluble prodrug of the compound of claims 1, 7, 9, 11, or 13, wherein said water-soluble prodrug that is metabolized in vivo to produce an active drug which selectively inhibit A1 adenosine receptor.

### Claim 20 (depends on 19)

The prodrug of claim 19, wherein said prodrug is metabolized in vivo by esterase catalyzed hydrolysis.

### Claim 21 (depends on 19)

A pharmaceutical composition comprising the prodrug of claim 19 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1, 7, 9, 11)

A method for inhibiting the activity of an A1 adenosine receptor in a cell, which comprises contacting said cell with a compound of claims 1, 7, 9, 11, or 13.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound is an antagonist of said A1 adenosine receptor.

### Claim 24 (depends on 22)

The method of claim 22, wherein the cell is human cell.

### Claim 25 (depends on 22)

The method of claim 22, wherein the compound is an antagonist of A1 adenosine receptors.

### Claim 26 (depends on 15)

The method of claim 15, wherein said disease is asthma, chronic obstructive pulmonary disease, allergic rhinitis, or an upper respiratory disorder.

### Claim 27 (depends on 26)

The method of claim 26, wherein the subject is a human.

### Claim 28 (depends on 26)

The method of claim 26, wherein said compound is an antagonist of A1 adenosine receptors.

### Claim 29 (depends on 1, 7, 9, 11)

A combination therapy for asthma, comprising the compound of claims 1, 7, 9, 11, or 13, and a steroid, β2 agonist, glucocoticoid, lucotriene antagonist, or anticolinegic agonist.

### Claim 30 (depends on 1, 7, 9, 11)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claims 1, 7, 9, 11, or 13 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein said respiratory disorder is asthma, allergic rhinitis, or chronic obstructive pulmonary disease.

### Claim 32 (depends on 30)

The pharmaceutical composition of claim 30, wherein said pharmaceutical composition is an periocular, retrobulbar or intraocular injection formulation.

### Claim 33 (depends on 30)

The pharmaceutical composition of claim 30, wherein said pharmaceutical composition is a systemic formulation.

### Claim 34 (depends on 30)

The pharmaceutical composition of claim 30, wherein said pharmaceutical composition is a surgical irrigating solution.

### Claim 35 (depends on 1, 7, 9, 11)

A packaged pharmaceutical composition for treating a disease associated with A1 adenosine receptor in a subject, comprising:
(a) a container holding a therapeutically effective amount of the compound of claims 1, 7, 9, 11, or 13; and
(b) instructions for using said compound for treating said disease in a subject.

### Claim 36

A method of preparing compounds VI, VII, VIII, IX, or X, comprising the steps of
a) reacting
295
wherein P is a removable protecting group;
b) treating the product of step a) under cyclization conditions to provide
296
c) treating the product of step b) under suitable conditions to provide
297
and
d) treating the chlorinated product of step c) with NH2R1 to provide
298
wherein R1 is 2-(methylamino carbonylamino)-cyclohexyl, acetylamino ethyl, methylamino carbonylamino ethyl, or trans-4-hydroxy cyclohexyl;
wherein R2 is a four to six membered ring; and
wherein R3 and R4 are independently H, or alkyl.
